The specific objective of this contract will be to provide the Investigational Drug Branch (IDB), CTEP, DCT, NCI, with Phase I clinical evaluations of investigational new drugs which are developed through the DCT Linear Array and are sponsored to the Food and Drug Administration (FDA) under an IND held by DCT. The objective of Phase I studies is to provide the parameters and characteristics of drug toxicity, the maximally tolerated dose, and a recommended Phase II dose.
| Lee, E J; Reck, K; Schiffer, C A (1990) Continuous infusion diaziquone and etoposide: a phase I study in adult patients with acute leukemia. Leukemia 4:189-92 |
| Egorin, M J; Sigman, L M; Van Echo, D A et al. (1987) Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. Cancer Res 47:617-23 |
| Sigman, L M; Van Echo, D A; Egorin, M J et al. (1986) Phase I trial of menogaril administered as an intermittent daily infusion for 5 days. Cancer Treat Rep 70:721-5 |
| Lee, E J; Van Echo, D A; Egorin, M J et al. (1986) Diaziquone given as a continuous infusion is an active agent for relapsed adult acute nonlymphocytic leukemia. Blood 67:182-7 |
| O'Dwyer, P J; Donehower, M; Sigman, L M et al. (1985) Phase I trial of N-methylformamide (NMF, NSC 3051). J Clin Oncol 3:853-7 |
